Skip to content

Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation

Multicenter International Observational Study to Identify Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation and Their Specific Determinants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04117152
Acronym
TRAJ-CAV
Enrollment
1300
Registered
2019-10-07
Start date
2004-01-01
Completion date
2020-06-30
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allograft Arteriopathy, Heart Transplantation

Brief summary

This project aims: i) to identify Cardiac Allograft Vasculopathy (CAV) trajectories after heat transplantation using latent class mixed modeling, ii) to characterize the global and specific determinants of different trajectories and iii) to provide an easily accessible tool to project individual probability of CAV trajectory belonging.

Detailed description

Background: Cardiac Allograft Vasculopathy (CAV) is the third cause of late mortality and the leading cause of late allograft dysfunction. The field of heart transplantation currently lacks longitudinal description of CAV profiles. Identifying relevant CAV trajectories, or evolution profiles, and their respective determinants is an unmet clinical need. CAV trajectories requires an additional level of understanding and characterization over the current paradigm. Understanding the mechanisms and clinical factors involved in the development of CAV will be useful to provide a more nuanced picture of disease progression, which may ultimately contribute to risk stratification and ultimately guiding the care of HTx patients. Main Outcome(s) and Measure(s): * Identification of CAV trajectories after transplantation using an unsupervised latent class mixed modeling. CAV angiograms were recorded per center protocol for all patients after transplantation. CAV was graded according to the current ISHLT classification as CAV 0 (not significant), 1 (mild), 2 (moderate) and 3 (severe). * Determination of clinical, functional, structural, immunological factors associated with the trajectories. In the derivation cohort, the associations between CAV trajectories and clinical, histological, functional, and immunological parameters at the time of transplantation, during the first year and at one-year post-transplant were assessed using multinomial logistic regression.

Interventions

OTHERLatent class mixed modeling

To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling

Sponsors

Groupe Hospitalier Pitie-Salpetriere
CollaboratorOTHER
European Georges Pompidou Hospital
CollaboratorOTHER
Universitaire Ziekenhuizen KU Leuven
CollaboratorOTHER
Cedars-Sinai Medical Center
CollaboratorOTHER
Paris Translational Research Center for Organ Transplantation
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Heart recipient with at least two coronary angiograms after heart transplantation, * Heart recipient over 18 years of age.

Exclusion criteria

* Patient with \< 2 coronary angiograms during follow-up

Design outcomes

Primary

MeasureTime frameDescription
Identification of trajectories of Cardiac Allograft Vasculopathy (CAV)10 years post-transplantIdentification of different evolutive profiles of CAV using latent classes mixed models. Each coronary angiogram was graded from 0 (no CAV) to 3 (severe CAV) according to ISHLT classification.

Secondary

MeasureTime frameDescription
Identification of the specific determinants of CAV trajectoriesFrom transplantation to 1-year post-transplantIdentification of immune and non-immune determinants using multivariable multinomial logistic regression.
Early prediction of CAV trajectories10 years post-transplantProbability of belonging to each trajectory according to the baseline angiogram and independent risk factors for CAV
Patients and allograft survival probability according the CAV trajectory10 years post-transplantComparison of prognosis according the CAV trajectory

Countries

Belgium, France, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026